Your Source for Venture Capital and Private Equity Financings

Venture Capital News: EpiBiologics Launches with $50M Series A Financing

2023-03-22
SAN MATEO, CA, EpiBiologics launches with $50 million in Series A funding led by Mubadala Capital and Polaris Partners.
EpiBiologics, a biotechnology company building a next-generation antibody-based protein degradation platform for membrane and extracellular drug targets, launched with $50 million in Series A funding. The funding was co-led by Mubadala Capital and Polaris Partners, with participation from Vivo Capital and GV. The company's technology platform is based on the scientific work of EpiBiologics' co-founder and renowned antibody engineer Dr. Jim Wells of the University of California, San Francisco (UCSF), and the platform intellectual property has been exclusively licensed from UCSF.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors